Home / Products / Polyclonal antibody /

Sclerostin Polyclonal Antibody

Product code: YP-Ab-04188
Promotional price:

Product introduction

Reactive species
Human;Rat;Mouse;
Applications
WB;ELISA;IHC
Antibody type
Polyclonal Antibody
Gene Name
SOST
Protein name
Sclerostin
Dalton(DA)
26kD
Immunogen
Synthesized peptide derived from Sclerostin . at AA range: 130-210
Specificity
Sclerostin Polyclonal Antibody detects endogenous levels of Sclerostin protein.
Constitute
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Source
Polyclonal, Rabbit,IgG
Dilution rate
WB 1:500-2000;IHC-p 1:50-300; ELISA 2000-20000
Purification process
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
1 mg/ml
Stockpile
-20°C/1 year
Other name
SOST; Sclerostin
Background
Sclerostin is a secreted glycoprotein with a C-terminal cysteine knot-like (CTCK) domain and sequence similarity to the DAN (differential screening-selected gene aberrative in neuroblastoma) family of bone morphogenetic protein (BMP) antagonists. Loss-of-function mutations in this gene are associated with an autosomal-recessive disorder, sclerosteosis, which causes progressive bone overgrowth. A deletion downstream of this gene, which causes reduced sclerostin expression, is associated with a milder form of the disorder called van Buchem disease. [provided by RefSeq, Jul 2008],
Function
disease:A 52 kb deletion downstream of SOST results in SOST transcription suppression and is a cause of van Buchem disease (VBCH) [MIM:239100]; also known as hyperostosis corticalis generalisata. VBCH is an autosomal recessive sclerosing bone dysplasia characterized by endosteal hyperostosis of the mandible, skull, ribs, clavicles, and diaphyses of the long bones. Affected patients present a symmetrically increased thickness of bones, most frequently found as an enlarged jawbone, but also an enlargement of the skull, ribs, diaphysis of long bones, as well as tubular bones of hands and feet. The clinical consequence of increased thickness of the skull include facial nerve palsy causing hearing loss, visual problems, neurological pain, and, very rarely, blindness as a consequence of optic atrophy. Serum alkaline phosphatase levels are elevated.,disease:Defects in SOST are the cause of scle

Open

Product Details

Customer data and reviews (0)

Fold content

Citation

Fold content

Experimental scheme

Fold content
>